HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis

• DOI: 10.1111/j.1365-2133.2011.10688.x
• Publication Date: 2011-10-10T17:54:03Z
• Authors: H.Y. Chiu; P.-Y. Huang; S.-H. Jee; C.-Y. Hu; C.-T. Chou; Y.-T. Chang; C.-Y. Hwang; T.-F. Tsai
• Keywords: Ustekinumab; HLA-C; HLA-B

HLA-Cw*06 has a strong influence on the clinical features and susceptibility to psoriasis in different ethnicities. It is also used as biomarker predict therapeutic efficacy of biologics, with inconsistent results. Additionally, most Asian patients do not carry HLA-Cw*06.To determine additional HLA alleles which confer or affect severity Chinese Han individuals. In addition, potential using treatment outcomes was investigated.We conducted case-control association study 199 200 unrelated healthy controls. HLA-B HLA-C genotyping performed correlated including alefacept, efalizumab, etanercept ustekinumab. Patients were divided into group A (high-need moderate severe psoriasis) B (general psoriasis).The frequencies HLA-B*60, HLA-B*75, HLA-Cw*10 significantly increased compared However, prevalence lower (6% vs. 17%, Pc=0·04). HLA-B*46 found be strongly associated but psoriasis. HLA-Cw*01/HLA-B*46 identified risk haplotype for psoriasis, compatible results Thais. Significant differences response biologics observed between HLA-Cw*01+ HLA-Cw*01- individuals alefacept group, HLA-B*37+ HLA-B*37-, HLA-B*58+ HLA-B*58- efalizumab group.In addition HLA-Cw*06, High-need had frequency higher general our population.